الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 109 |  |  |
| | | from | 109 | | |
Abstract
MS is an immune-mediated, chronic disease of the central nervous system that affects mainly the adults. However, it is increasingly recognized that MS may start in the childhood resulting in a relentlessly progressive disability and cognitive impairment. When the age of MS patients at disease onset is younger than 18 years, Pediatric-onset MS (POMS) is defined. Being aware that MS disease, with time, has a detrimental effect on both the cognition and the function of the affected individuals, the earlier the onset, the worse endpoints we are anticipating. Thus, POMS is starting to receive more attention regarding the epidemiology of the disease, disease course, and the response profile to the emerging disease-modifying treatments (DMTs). Registries across the globe are reporting inconstant data about their MS patients.
We aimed in our study to compare the clinical characteristics of patients with (POMS) to (AOMS) in a sample of Egyptian patients at Alexandria university, and to identify predictors for disability progression in POMS.
This study was